PROMEDIOR

promedior-logo

Promedior is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and fibrotic diseases Promedior has developed a novel drug discovery platform to regulate the monocyte-derived cell populations that play key roles in fibrotic, inflammatory and autoimmune diseases. By specifically targeting these cells at the site of injury, Promedior is able to treat the source of aberrant immune system responses, promote tissue healing and resolution, an... d greatly reduce the risk of systemic side effects inherent in current therapeutic approaches. Promedior is developing drugs to address the most severe and difficult-to-treat fibrotic and inflammatory conditions of the eye, lung and kidney such as glaucoma, age-related macular degeneration, diabetic retinopathy and dry eye disease; pulmonary fibrosis, scleroderma and COPD; and acute and chronic nephropathy.

#SimilarOrganizations #People #Financial #Website #More

PROMEDIOR

Industry:
Biopharma Biotechnology Health Care Therapeutics

Founded:
2006-01-01

Address:
Lexington, Massachusetts, United States

Country:
United States

Website Url:
http://www.promedior.com

Total Employee:
51+

Status:
Active

Contact:
781-538-4200

Email Addresses:
[email protected]

Total Funding:
63 M USD

Technology used in webpage:
Viewport Meta Domain Not Resolving SPF Google Maps Mobile Non Scaleable Content IPv6 Microsoft Mimecast Akamai DNS


Similar Organizations

acologix-logo

Acologix

Acologix is a biopharmaceutical company developing therapeutic compounds for the treatment of osteo-renal diseases.

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

baergic-bio-logo

Baergic Bio

Baergic Bio is a biopharmaceutical company that develops and commercialises novel therapeutics for the treatment of CNS disorders.

complexa-logo

Complexa

Complexa, a biopharmaceutical company, develops therapies for the treatment of inflammatory, and metabolic diseases.

cytokinetics-logo

Cytokinetics

Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.

revision-therapeutics-logo

ReVision Therapeutics

ReVision Therapeutics, a biopharmaceutical company, develops drugs for the treatment of age-related macular degeneration diseases.

soligenix-logo

Soligenix

Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.


Current Advisors List

geert-jan-mulder_image

Geert Jan Mulder Board of Directors @ Promedior
Board_member

not_available_image

Nancy K. Thomason Board of Directors @ Promedior
Board_member

john-h-friedman_image

John H. Friedman Board of Directors @ Promedior
Board_member

paul-d-goldenheim_image

Paul D. Goldenheim Board of Directors @ Promedior
Board_member

gus-lawlor_image

Gus Lawlor Board of Directors @ Promedior
Board_member

Current Employees Featured

not_available_image

Richard Jack
Richard Jack Senior Scientific Consultant to Promedior, A Member of the Roche Group @ Promedior
Senior Scientific Consultant to Promedior, A Member of the Roche Group
2020-09-01

Founder


jim-broderick_image

Jim Broderick

Investors List

sofinnova-ventures_image

Sofinnova Investments

Sofinnova Investments investment in Venture Round - Promedior

shire_image

Shire

Shire investment in Series D - Promedior

healthcare-ventures_image

HealthCare Ventures

HealthCare Ventures investment in Series D - Promedior

forbion-capital-partners_image

Forbion Capital Partners

Forbion Capital Partners investment in Series D - Promedior

fibrotic-ventures_image

Fibrotic Ventures

Fibrotic Ventures investment in Series D - Promedior

polaris-partners_image

Polaris Partners

Polaris Partners investment in Series D - Promedior

morgenthaler-ventures_image

Morgenthaler Ventures

Morgenthaler Ventures investment in Series D - Promedior

easton-capital_image

Easton Capital

Easton Capital investment in Series D - Promedior

easton-capital_image

Easton Capital

Easton Capital investment in Series D - Promedior

fibrotic-ventures_image

Fibrotic Ventures

Fibrotic Ventures investment in Series D - Promedior

Official Site Inspections

http://www.promedior.com

  • Host name: heps.roche.com
  • IP address: 198.21.19.135
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Promedior"

Promedior Company Profile 2024: Valuation, Investors ... - PitchBook

Promedior General Information Description. Developer of therapeutics designed to treat fibrotic diseases. The company is focused on rare fibrotic diseases including idiopathic pulmonary โ€ฆSee details»

Promedior, Inc. - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for Promedior, Inc. of South San Francisco, CA. Get the latest business insights from Dun & Bradstreet.See details»

Promedior | VentureRadar

Website: http://www.promedior.com/ Develops targeted therapeutics for fibrosis treatment using proprietary platform based on Pentraxin-2, aiming to prevent and ...See details»

Promedior Inc - Company Profile and News - Bloomberg Markets

Promedior, Inc. manufactures pharmaceutical products. The Company develops therapeutics for a wide variety of serious fibrotic diseases of the lung, kidney, and eye, as well as pulmonary โ€ฆSee details»

Promedior - Company Profile - Tracxn

Nov 25, 2024 Promedior is a clinical-stage biotechnology company that develops targeted therapeutics to treat diseases involving fibrosis. Promedior's proprietary platform is based โ€ฆSee details»

Promedior - Company profile | ensun

Health Care, Other Investment Pools and Funds, Manufacturing, Other Financial Investment Activities, Management investment, open-end, Sugar and Confectionery Product โ€ฆSee details»

Roche acquires Promedior - 2019-11-15 - Crunchbase

Nov 15, 2019 Acquired Organization: Promedior Promedior is a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and fibrotic diseases. โ€ฆSee details»

Promedior - Tech Company Profile - Gaebler.com Venture Capital โ€ฆ

Promedior is a product-focused biopharmaceutical company developing novel therapeutics for the treatment of fibrotic disorders and diseases.See details»

Promedior, Inc. Company Profile: Financials, Valuation, and Growth

Promedior, Inc. is a pharmaceutical development and manufacturing company. Promedior, Inc. was founded in 2006 by Jim Broderick. Promedior, Inc. headquarters are located in Malvern, โ€ฆSee details»

Promedior, Inc.:Company Profile & Technical Research,Competitor โ€ฆ

Promedior, Inc. is a company that provides Pharmacy and Therapeutics, Medicine, Pulmonary fibrosis and more. Promedior, Inc. is headquartered in United States Massachusetts.See details»

Promedior - EquityNet

Promedior is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and fibrotic diseases Promedior has developed a novel drug โ€ฆSee details»

Promedior - Funding, Financials, Valuation & Investors - Crunchbase

How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial โ€ฆSee details»

Promedior - Crunchbase

Promedior is a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and fibrotic diseases.See details»

Promedior IPO - Linqto

Promedior, founded in 2006 and headquartered in Lexington, Massachusetts, is a clinical-stage immunotherapy company focused on developing targeted therapeutics for fibrosis-related โ€ฆSee details»

Promedior Enters Into Definitive Merger Agreement To Be โ€ฆ

LEXINGTON, Mass., Nov. 15, 2019 /PRNewswire/ -- Promedior, Inc., today announced that it has entered into a definitive merger agreement for Roche (SIX: RO, ROG; OTCQX: RHHBY) to โ€ฆSee details»

Promedior - Founders and Board of Directors - Tracxn

Nov 17, 2024 Promedior's founder is Jim Broderick. Promedior founders & board of directors. Targeted protein-based therapeutics to treat fibrotic diseases such as Idiopathic Pulmonary โ€ฆSee details»

Promedior - Contacts, Employees, Board Members, Advisors

Organization. Promedior . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. Number of Board โ€ฆSee details»

Promediol SA Company Profile | Montagnola, TICINO, Switzerland ...

Find company research, competitor information, contact details & financial data for Promediol SA of Montagnola, TICINO. Get the latest business insights from Dun & Bradstreet.See details»

Promediol โ€“ Swiss Therapeutic Solutions

Promediol SA is a Swiss company focused on health and quality of life. Our headquarter is located in canton Ticino, in the heart of Switzerland and Europe, just a few hours from France, โ€ฆSee details»

Promedior - Tech Stack, Apps, Patents & Trademarks - Crunchbase

Promedior is a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and fibrotic diseases.See details»

linkstock.net © 2022. All rights reserved